N-{3-[6-chloro-1-(3-methyl-4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-1-propyl}-N-methylglycine | 847030-26-6

• 分子结构分类: 有机化合物
• 英文名称: N-{3-[6-chloro-1-(3-methyl-4-fluorophenyl)-1,3-dihydroisobenzofuran-1-yl]-1-propyl}-N-methylglycine
• 英文别名: 2-[3-[6-chloro-1-(4-fluoro-3-methylphenyl)-3H-2-benzofuran-1-yl]propyl-methylamino]acetic acid
• CAS: 847030-26-6
• 化学式: C₂₁H₂₃ClFNO₃
• 分子量: 391.87
• InChiKey: JVQZDCZIFSRDQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Novel compounds and their use as glycine transport inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20030181445A1

  公开（公告）日：2003-09-25

  The invention provides novel compounds of the formula I below: 1 wherein the meaning of each substituent is defined in the application. The compounds are useful as inhibitors of the glycine transporter and useful in the treatment of diseases responsive to the inhibition of the glycine transporter. The invention provides a pharmaceutical composition comprising a compound of Formula I as defined above and the use of compounds as above for the manufacture of medicaments for treatment of diseases responsive to ligands of the glycine transporter.

  本发明提供了以下式子I的新化合物：1其中每个取代基的含义在申请中定义。这些化合物可用作甘氨酸转运体的抑制剂，并且可用于治疗对甘氨酸转运体抑制剂敏感的疾病。本发明提供了一种药物组合物，包括上述式子I中定义的化合物，以及将上述化合物用于制造对甘氨酸转运体配体敏感的疾病的药物。
• SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：EP3006023A1

  公开（公告）日：2016-04-13

  Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

  本文提供了治疗神经精神疾病（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症和双相情感障碍）的方法和组合物。这些方法需要给被诊断为患有神经精神障碍（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症、双相情感障碍等）或有神经精神障碍风险的患者施用苯甲酸、苯甲酸盐和/或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物，并与神经药剂（如抗精神病药、抗精神病药、抗精神病药、抗精神病药）结合使用、苯甲酸、苯甲酸盐或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物的用量足以提高神经药剂的药效。
• Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
  申请人：Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

  公开号：US10039730B2

  公开（公告）日：2018-08-07

  Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.

  本文提供了治疗神经精神疾病（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症和双相情感障碍）的方法和组合物。这些方法需要给被诊断为患有神经精神障碍（如精神分裂症、抑郁症、注意力缺陷障碍、轻度认知障碍、痴呆症、双相情感障碍等）或有神经精神障碍风险的患者施用苯甲酸、苯甲酸盐和/或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物，并与神经药剂（如抗精神病药、抗精神病药、抗精神病药、抗精神病药）结合使用、其中苯甲酸、苯甲酸盐或苯甲酸衍生物和/或山梨酸、山梨酸盐和/或山梨酸衍生物的用量足以提高神经药剂的药效。
• Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
  申请人：Didriksen Michael

  公开号：US20060223857A1

  公开（公告）日：2006-10-05

  The present invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and a compound, which is a GlyT-1 inhibitor for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders. In particular the present invention relates to treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors. The present invention also relates to a pharmaceutical composition comprising a serotonin reuptake inhibitor, and a GlyT-1 inhibitor.

  本发明涉及一种化合物（5-羟色胺再摄取抑制剂）和一种化合物（GlyT-1抑制剂）用于制备治疗抑郁症、焦虑症和其他情感障碍的药物组合物。本发明尤其涉及抑郁症、焦虑症和其他情感障碍的治疗，如广泛性焦虑症、恐慌焦虑症、强迫症、急性应激障碍、创伤后应激障碍和社交焦虑症、进食障碍，如贪食症、厌食症和肥胖症、恐惧症、癔症、经前期综合征、认知障碍、冲动控制障碍、注意缺陷多动障碍、药物滥用或任何其他对血清素再摄取抑制剂有反应的障碍。本发明还涉及一种药物组合物，该组合物包含血清素再摄取抑制剂和 GlyT-1 抑制剂。
• COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：EP1301502B1

  公开（公告）日：2005-05-18